Health Care Drops on Regulatory Fears - Health Care Roundup
Provided by
Dow Jones
Health-care companies fell amid doubts about regulations in light of the upcoming presidential election.
Pfizer fell despite Pfizer generating roughly $3.56 billion proceeds from sales of some holdings in British consumer-drug concern Haleon and a share buyback.
Health-care CVS Health has spent more than $88 billion in the last half-dozen years to add a major health insurer, a clinic operator and a home-visit provider to its namesake pharmacies, but the troubled chain is now weighing a breakup of the company.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
October 01, 2024 17:33 ET (21:33 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now
-
New 4-Star Stocks
United States